Literature DB >> 16220524

Efficient group sequential designs when there are several effect sizes under consideration.

Christopher Jennison1, Bruce W Turnbull.   

Abstract

We consider the construction of efficient group sequential designs where the goal is a low expected sample size not only at the null hypothesis and the alternative (taken to be the minimal clinically meaningful effect size), but also at more optimistic anticipated effect sizes. Pre-specified Type I error rate and power requirements can be achieved both by standard group sequential tests and by more recently proposed adaptive procedures. We investigate four nested classes of designs: (A) group sequential tests with equal group sizes and stopping boundaries determined by a monomial error spending function (the 'rho-family'); (B) as A but the initial group size is allowed to be different from the others; (C) group sequential tests with arbitrary group sizes and arbitrary boundaries, fixed in advance; (D) adaptive tests-as C but at each analysis, future group sizes and critical values are updated depending on the current value of the test statistic. By examining the performance of optimal procedures within each class, we conclude that class B provides simple and efficient designs with efficiency close to that of the more complex designs of classes C and D. We provide tables and figures illustrating the performances of optimal designs within each class and defining the optimal procedures of classes A and B. Copyright (c) 2005 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2006        PMID: 16220524     DOI: 10.1002/sim.2251

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

Review 1.  Adaptive trial designs.

Authors:  Tze Leung Lai; Philip William Lavori; Mei-Chiung Shih
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011-08-11       Impact factor: 13.820

2.  Sequential design of phase II-III cancer trials.

Authors:  Tze Leung Lai; Philip W Lavori; Mei-Chiung Shih
Journal:  Stat Med       Date:  2012-03-16       Impact factor: 2.373

3.  Adaptive designs for comparative effectiveness research trials.

Authors:  John A Kairalla; Christopher S Coffey; Mitchell A Thomann; Ronald I Shorr; Keith E Muller
Journal:  Clin Res Regul Aff       Date:  2014-11-13

4.  Adaptive design of confirmatory trials: Advances and challenges.

Authors:  Tze Leung Lai; Philip W Lavori; Ka Wai Tsang
Journal:  Contemp Clin Trials       Date:  2015-06-14       Impact factor: 2.226

5.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

6.  Sample size re-estimation in an on-going NIH-sponsored clinical trial: the secondary prevention of small subcortical strokes experience.

Authors:  Leslie A McClure; Jeff M Szychowski; Oscar Benavente; Christopher S Coffey
Journal:  Contemp Clin Trials       Date:  2012-06-30       Impact factor: 2.226

7.  Trial Sequential Analysis in systematic reviews with meta-analysis.

Authors:  Jørn Wetterslev; Janus Christian Jakobsen; Christian Gluud
Journal:  BMC Med Res Methodol       Date:  2017-03-06       Impact factor: 4.615

8.  Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment.

Authors:  Guoqiao Wang; Richard E Kennedy; Gary R Cutter; Lon S Schneider
Journal:  Alzheimers Dement (N Y)       Date:  2015-04-14

Review 9.  Adaptive trial designs: a review of barriers and opportunities.

Authors:  John A Kairalla; Christopher S Coffey; Mitchell A Thomann; Keith E Muller
Journal:  Trials       Date:  2012-08-23       Impact factor: 2.279

10.  The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials.

Authors:  Janus Christian Jakobsen; Christian Gluud; Per Winkel; Theis Lange; Jørn Wetterslev
Journal:  BMC Med Res Methodol       Date:  2014-03-04       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.